Two-Step Electroporation for Macrophage Transfection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for transfecting human macrophages with genetic material are inefficient, result in high cell death, and are not compatible with Good Manufacturing Practice (GMP) protocols, making it difficult to produce clinically usable genetically modified primary human macrophages for cell therapy.
Innovation Solution
A two-step electroporation method using specific pulse phases, with a first pulse of 750-1000 V for 20-500 μs and a second pulse of 50-225 V for 2000-50000 μs, to efficiently introduce genetic material into human macrophages while repressing the STING pathway, thereby reducing IFN-β expression and maintaining cell viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current electroporation methods are used to transfect human macrophages, then genetic material can be introduced into the cells, but cell death increases and transfection efficiency remains low
Solution Approach 1:
The electroporation process is divided into two distinct pulse phases: a first pulse phase (750-1000 V, 20-500 μs) for initial membrane permeabilization and a second pulse phase (50-225 V, 2000-50000 μs) for enhanced genetic material uptake. This segmentation allows optimization of each phase to balance transfection efficiency and cell survival
Solution Approach 2:
The invention optimizes specific electroporation parameters including voltage (750-1000 V for first phase, 50-225 V for second phase), pulse duration (20-500 μs for first phase, 2000-50000 μs for second phase), and pulse frequency to achieve high transfection efficiency while maintaining cell viability above 60%
2Productivity
If viral methods are used to genetically modify macrophages, then gene delivery efficiency improves, but safety risks increase due to potential neoplastic transformation
Solution Approach 1:
The invention uses non-integrating plasmid DNA as a temporary, non-permanent genetic modification approach. The plasmid provides transient gene expression without integrating into the host genome, eliminating risks of insertional mutagenesis and neoplastic transformation while maintaining adequate gene delivery efficiency for therapeutic applications
Solution Approach 2:
The invention extracts and eliminates the harmful integrating capability from viral vectors by using naked plasmid DNA electroporation. This removes the risk of genomic integration and potential cancer transformation while retaining the ability to deliver therapeutic genes temporarily
3Productivity
If macrophages are transfected with genetic material, then therapeutic function is enhanced, but immune response activation increases
Solution Approach 1:
The optimized electroporation protocol prepares macrophages for genetic material uptake in a controlled manner that minimizes immune activation. By using specific pulse parameters, the method allows efficient plasmid entry while maintaining macrophage tolerance and preventing premature immune response activation
Solution Approach 2:
The invention adjusts electroporation parameters to create optimal conditions for plasmid uptake that do not trigger strong immune responses. The specific voltage and duration ranges enable gentle membrane permeabilization that favors therapeutic gene uptake over immune activation pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves high transfection efficiency and viability (>60%) of genetically modified human macrophages, compatible with GMP standards, and effectively reduces IFN-β expression, enabling their use in cell therapy applications.
Implementation Method 1
Electroporation is compatible with Good Manufacturing Practice (GMP) manufacturing protocols, it could be a potential route to producing clinically useful cell products
Data Source
AI summary
The development of the method of the invention enables the efficient and reproducible production of genetically modified GMP-grade human macrophages. The inventors have described the effects of the method described on cell viability and efficiency of introduction of genetic material into macrophages. Unlike previous methods of introducing genetic material into macrophages, excellent conditions are demonstrated which produce efficient transgene expression, without compromising cell viability. Critically, the method of the invention does not use virus to introduce genetic material, is efficacious on mature cells, are functional with in vitro assay and in vivo transfer in a liver disease model and complies with practices compatible with manufacture and delivery of these cells to patients.